Julyan Keller-Baruch

Julyan Keller-Baruch

Auto-generated profile, based on publicly available information

Julyan Keller-Baruch

Department of Human Genetics, McGill University, Montreal, Quebec, Canada

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2020 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
VFVincenzo Forgetta
Vincenzo Forgetta
JKJulyan Keller-Baruch
Julyan Keller-Baruch
MFMarie Forest
Marie Forest
ADAudrey Durand
Audrey Durand
SBSahir Bhatnagar
Sahir Bhatnagar
JRJ. Brent Richards
J. Brent Richards
Since screening programs identify only a small proportion of the population as eligible for an intervention, genomic prediction of heritable risk factors could decrease the number needing to be screened by removing individuals at low genetic risk. We therefore tested whether a polygenic risk score for heel quantitative ultrasound speed of sound (SOS)—a heritable risk factor for osteoporotic fracture—can identify low-risk individuals who can safely be excluded from a fracture risk screening program. A polygenic risk score for SOS was trained and selected in 2 separate subsets of UK Biobank (comprising 341,449 and 5,335 individuals). The top-performing prediction model was termed “gSOS”, and its utility in fracture risk screening was tested in 5 validation cohorts using the National Osteoporosis Guideline Group clinical guidelines (N = 10,522 eligible participants). All individuals were genome-wide genotyped and had measured fracture risk factors. Across the 5 cohorts, the average age ranged from 57 to 75 years, and 54% of studied individuals were women. The main outcomes were the sensitivity and specificity to correctly identify individuals requiring treatment with and without genetic prescreening. The reference standard was a bone mineral density (BMD)–based Fracture Risk Assessment Tool (FRAX) score. The secondary outcomes were the proportions of the screened population requiring clinical-risk-factor-based FRAX (CRF-FRAX) screening and BMD-based FRAX (BMD-FRAX) screening. gSOS was strongly correlated with measured SOS (r2 = 23.2%, 95% CI 22.7% to 23.7%). Without genetic prescreening, guideline recommendations achieved a sensitivity and specificity for correct treatment assignment of 99.6% and 97.1%, respectively, in the validation cohorts. However, 81% of the population required CRF-FRAX tests, and 37% required BMD-FRAX tests to achieve this accuracy. Using gSOS in prescreening and limiting further assessment to those with a low gSOS resulted in small changes to the sensitivity and specificity (93.4% and 98.5%, respectively), but the proportions of individuals requiring CRF-FRAX tests and BMD-FRAX tests were reduced by 37% and 41%, respectively. Study limitations include a reliance on cohorts of predominantly European ethnicity and use of a proxy of fracture risk. Our results suggest that the use of a polygenic risk score in fracture risk screening could decrease the number of individuals requiring screening tests, including BMD measurement, while maintaining a high sensitivity and specificity to identify individuals who should be recommended an intervention.

1 December 2019 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
PDF file
JKJulyan Keller-Baruch
Julyan Keller-Baruch
VFVincenzo Forgetta
Vincenzo Forgetta
DMDespoina Manousaki
Despoina Manousaki
SZSirui Zhou
Sirui Zhou
JRJ Brent Richards
J Brent Richards
Vascular endothelial growth factor (VEGF) is important for bone formation and has been associated with osteoporosis in humans. Therefore, we conducted a two-sample Mendelian randomization study to test whether genetically decreased circulating VEGF was associated with decreased bone mineral density (BMD) and increased risk of fracture. Summary statistics from a genomewide association study (GWAS) meta-analysis of circulating VEGF level (n = 16,112) were used to identify 10 genetic variants explaining up to 52% of the variance in circulating VEGF levels. GWAS meta-analyses on dual-energy X-ray absorptiometry (DXA)-derived BMD of forearm, lumbar spine, and femoral neck (n = up to 32,735) and BMD estimated from heel calcaneus ultrasound (eBMD) (n = 426,824) were used to assess the effect of genetically lowered circulating VEGF levels on BMD. A GWAS meta-analysis including a total of 76,549 cases and 470,164 controls was used to assess the effect of genetically lowered circulating VEGF levels on risk of fracture. A natural log-transformed pg/mL decrease in circulating VEGF levels was not associated with a decrease in forearm BMD (0.02 standard deviation [SD], 95% confidence interval [CI] −0.024 to 0.064, p = 0.38), lumbar spine BMD (−0.005 SD, 95% CI −0.03 to 0.019, p = 0.67), femoral neck BMD (0.004 SD, 95% CI −0.017 to 0.026, p = 0.68), eBMD (−0.006 SD, 95% CI −0.012 to −0.001, p = 0.031) or risk of fracture (odds ratio = 0.99, 95% CI 0.98 to 1.0, p = 0.37) in inverse-variance–weighted Mendelian randomization analyses. Sensitivity analyses did not provide evidence that our results were influenced by pleiotropy. Genetically lowered circulating VEGF was not associated with a decrease in BMD or increased risk of fracture, suggesting that efforts to influence circulating VEGF level are unlikely to have beneficial effects on osteoporosis outcomes and that previous observational associations of circulating VEGF with BMD were influenced by confounding or reverse causation. © 2019 American Society for Bone and Mineral Research.

8 June 2020 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
PDF file
DMDespoina Manousaki
Despoina Manousaki
VFVincenzo Forgetta
Vincenzo Forgetta
JKJulyan Keller-Baruch
Julyan Keller-Baruch
KZKaiqiong Zhao
Kaiqiong Zhao
CGCelia Mt Greenwood
Celia Mt Greenwood
JRJ Brent Richards
J Brent Richards
Some commonly prescribed drugs are associated with increased risk of osteoporotic fractures. However, fracture risk stratification using skeletal measures is not often performed to identify those at risk before these medications are prescribed. We tested whether a genomically predicted skeletal measure, speed of sound (gSOS) from heel ultrasound, which was developed in 341,449 individuals from UK Biobank and tested in a separate subset consisting of 80,027 individuals, is an independent risk factor for fracture in users of fracture‐related drugs (FRDs). To do this, we first assessed 80,014 UK Biobank participants (including 12,678 FRD users) for incident major osteoporotic fracture (MOF, n = 1189) and incident hip fracture (n = 209). Effects of gSOS on incident fracture were adjusted for baseline clinical fracture risk factors. We found that each standard deviation decrease in gSOS increased the adjusted odds of MOF by 42% (95% confidence interval [CI] 1.34–1.51, p < 2 × 10−16) and of hip fracture by 31% (95% CI 1.15–1.50, p = 9 × 10−5). gSOS below versus above the mean increased the adjusted odds of MOF by 79% (95% CI 1.58–2.01, p < 2 × 10−16) and of hip fracture by 42% (95% CI 1.08–1.88, p = 1.3 × 10−2). Among FRD users, each standard deviation decrease in gSOS increased the adjusted odds of MOF by 29% (n MOF = 256, 95% CI 1.14–1.46, p = 7 × 10−5) and of hip fracture by 30% (n hip fracture = 68, 95% CI 1.02–1.65, p = 0.0335). FRD users with gSOS below versus above the mean had a 54% increased adjusted odds of MOF (95% 1.19–1.99, p = 8.95 × 10−4) and a twofold increased adjusted odds of hip fracture (95% 1.19–3.31, p = 8.5 × 10−3). We therefore showed that genomically predicted heel SOS is independently associated with incident fracture among FRD users. © 2020 American Society for Bone and Mineral Research.